Related Experiment Video
Updated: Oct 17, 2026
Application of Mid-Pancreatectomy with End-to-End Anastomosis in Pancreatic Benign Tumors
Published on: February 9, 2024
Gastro-entero-pancreatic neuroendocrine tumors: Is now time for a new approach?
Rossana Berardi1, Mariangela Torniai1, Agnese Savini1
1Rossana Berardi, Mariangela Torniai, Agnese Savini, Silvia Rinaldi, Stefano Cascinu, Department of Medical Oncology, Università Politecnica delle Marche, 60100 Ancona, Italy.
Abstract:
Gastro-entero-pancreatic tumors (GEP-NETs) are rare neoplasms often characterized by an overexpression of somatostatin receptors. Thus, radiolabeled somatostatin analogues have showed an increasing relevance both in diagnosis and treatment, especially in low- and intermediate-differentiated GEP-NETs. These evidences have led to a growing development of new functional imaging techniques as 68Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) proved useful in the management of these neoplasms. However these tumors have a heterogeneous behavior also modifying their aggressiveness through time. Therefore sometimes 18F-fluorodeoxyglucose PET/CT appears to be more appropriate to obtain a better assessment of the disease. According to these considerations, the combination of different functional imaging techniques should be considered in the management of GEP-NETs patients allowing clinicians to choose the tailored therapeutic approach among available options.
Insights
Radiolabeled somatostatin analogues and advanced imaging like Gallium-68 DOTATATE PET/CT are vital for diagnosing and treating gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs). Combining imaging techniques offers tailored treatment for these heterogeneous cancers.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiology
Background:
- Gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) are rare and often overexpress somatostatin receptors.
- Radiolabeled somatostatin analogues are increasingly used for diagnosing and treating GEP-NETs, particularly low- and intermediate-differentiated types.
Purpose of the Study:
- To review the role of functional imaging in managing GEP-NETs.
- To highlight the utility of Gallium-68 DOTATATE PET/CT and consider the complementary role of Fluorine-18 fluorodeoxyglucose PET/CT.
Main Methods:
- Review of current literature on functional imaging in GEP-NETs.
- Discussion of Gallium-68 DOTATATE PET/CT and Fluorine-18 fluorodeoxyglucose PET/CT applications.
- Consideration of combined imaging strategies.
Main Results:
- Gallium-68 DOTATATE PET/CT is effective in managing GEP-NETs due to somatostatin receptor overexpression.
- Tumor heterogeneity and evolving aggressiveness may necessitate the use of Fluorine-18 fluorodeoxyglucose PET/CT for comprehensive disease assessment.
- Combined imaging approaches can provide a more complete picture of the disease.
Conclusions:
- Functional imaging plays a crucial role in the management of GEP-NETs.
- A combination of imaging techniques, including Gallium-68 DOTATATE PET/CT and potentially Fluorine-18 fluorodeoxyglucose PET/CT, should be considered for personalized therapeutic strategies.
- Tailored management based on advanced imaging improves patient outcomes for GEP-NETs.
